vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Perella Weinberg Partners (PWP). Click either name above to swap in a different company.
Perella Weinberg Partners is the larger business by last-quarter revenue ($219.2M vs $191.2M, roughly 1.1× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -2.9%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 46.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
AXSM vs PWP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $219.2M |
| Net Profit | — | $13.8M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | 8.5% |
| Net Margin | — | 6.3% |
| Revenue YoY | 57.4% | -2.9% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $219.2M | ||
| Q3 25 | $171.0M | $164.6M | ||
| Q2 25 | $150.0M | $155.3M | ||
| Q1 25 | $121.5M | $211.8M | ||
| Q4 24 | $118.8M | $225.7M | ||
| Q3 24 | $104.8M | $278.2M | ||
| Q2 24 | $87.2M | $272.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $13.8M | ||
| Q3 25 | $-47.2M | $6.0M | ||
| Q2 25 | $-48.0M | $2.7M | ||
| Q1 25 | $-59.4M | $17.3M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $16.4M | ||
| Q2 24 | $-79.3M | $-66.0M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 8.5% | ||
| Q3 25 | -27.0% | 5.4% | ||
| Q2 25 | -24.5% | 5.8% | ||
| Q1 25 | -46.9% | 5.5% | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | 12.9% | ||
| Q2 24 | -89.5% | -30.2% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 6.3% | ||
| Q3 25 | -27.6% | 3.6% | ||
| Q2 25 | -32.0% | 1.8% | ||
| Q1 25 | -48.9% | 8.2% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | 5.9% | ||
| Q2 24 | -91.0% | -24.3% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $0.11 | ||
| Q3 25 | $-0.94 | $0.08 | ||
| Q2 25 | $-0.97 | $0.04 | ||
| Q1 25 | $-1.22 | $0.24 | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | $0.24 | ||
| Q2 24 | $-1.67 | $-1.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $255.9M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $-127.4M |
| Total Assets | $713.6M | $797.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $255.9M | ||
| Q3 25 | $325.3M | $185.5M | ||
| Q2 25 | $303.0M | $145.0M | ||
| Q1 25 | $300.9M | $111.2M | ||
| Q4 24 | $315.4M | $407.4M | ||
| Q3 24 | $327.3M | $335.1M | ||
| Q2 24 | $315.7M | $185.3M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $-127.4M | ||
| Q3 25 | $73.7M | $-302.4M | ||
| Q2 25 | $73.1M | $-318.4M | ||
| Q1 25 | $53.2M | $-323.1M | ||
| Q4 24 | $57.0M | $-421.4M | ||
| Q3 24 | $92.9M | $-360.8M | ||
| Q2 24 | $102.9M | $-283.0M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $797.6M | ||
| Q3 25 | $669.3M | $650.2M | ||
| Q2 25 | $639.8M | $606.7M | ||
| Q1 25 | $596.7M | $570.5M | ||
| Q4 24 | $568.5M | $876.8M | ||
| Q3 24 | $561.5M | $810.9M | ||
| Q2 24 | $548.2M | $645.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $34.8M |
| Free Cash FlowOCF − Capex | — | $30.5M |
| FCF MarginFCF / Revenue | — | 13.9% |
| Capex IntensityCapex / Revenue | — | 2.0% |
| Cash ConversionOCF / Net Profit | — | 2.52× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-34.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $34.8M | ||
| Q3 25 | $1.0M | $59.2M | ||
| Q2 25 | $-32.4M | $56.1M | ||
| Q1 25 | $-43.4M | $-176.5M | ||
| Q4 24 | $-26.2M | $223.4M | ||
| Q3 24 | $-18.6M | $200.3M | ||
| Q2 24 | $-30.1M | $90.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $30.5M | ||
| Q3 25 | $988.0K | $57.6M | ||
| Q2 25 | $-32.4M | $55.3M | ||
| Q1 25 | $-43.7M | $-177.6M | ||
| Q4 24 | $-26.2M | $207.0M | ||
| Q3 24 | $-18.7M | $199.3M | ||
| Q2 24 | $-30.2M | $83.7M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 13.9% | ||
| Q3 25 | 0.6% | 35.0% | ||
| Q2 25 | -21.6% | 35.6% | ||
| Q1 25 | -36.0% | -83.8% | ||
| Q4 24 | -22.1% | 91.7% | ||
| Q3 24 | -17.9% | 71.6% | ||
| Q2 24 | -34.6% | 30.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 2.0% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.3% | 0.5% | ||
| Q4 24 | 0.0% | 7.3% | ||
| Q3 24 | 0.1% | 0.4% | ||
| Q2 24 | 0.1% | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.52× | ||
| Q3 25 | — | 9.85× | ||
| Q2 25 | — | 20.50× | ||
| Q1 25 | — | -10.18× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 12.23× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
PWP
Segment breakdown not available.
